Equities

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Actions
  • Price (USD)32.30
  • Today's Change0.764 / 2.42%
  • Shares traded3.00
  • 1 Year change+2.39%
  • Beta--
Data delayed at least 20 minutes, as of Mar 10 2025 19:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Supernus Pharmaceuticals Inc grew revenues 8.94% from 607.52m to 661.82m while net income improved 5,512.84% from 1.32m to 73.87m.
Gross margin89.57%
Net profit margin11.16%
Operating margin12.34%
Return on assets5.58%
Return on equity7.55%
Return on investment7.16%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Supernus Pharmaceuticals Inc fell by 5.72m. However, the company earned 171.95m from its operations for a Cash Flow Margin of 25.98%. In addition the company generated 12.19m cash from financing while 189.87m was spent on investing.
Cash flow per share2.76
Price/Cash flow per share11.59
Book value per share18.58
Tangible book value per share7.12
More ▼

Balance sheet in USDView more

Supernus Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio2.35
Quick ratio2.16
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-8.87
EPS (TTM) vs
TTM 1 year ago
8,784.85
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.